Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neuroendocrine Tumors Unresectable”

527 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 527 results

Large-scale testing (Phase 3)Study completedNCT01515189
What this trial is testing

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Who this might be right for
Melanoma
Bristol-Myers Squibb 831
Testing effectiveness (Phase 2)Active Not RecruitingNCT05089370
What this trial is testing

Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma

Who this might be right for
Malignant Melanoma
University of Colorado, Denver 8
Testing effectiveness (Phase 2)Study completedNCT01152827
What this trial is testing

RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid

Who this might be right for
PheochromocytomaExtra-adrenal ParagangliomaNon-functioning Carcinoid
Seoul National University Hospital 33
Testing effectiveness (Phase 2)Study completedNCT03278665
What this trial is testing

4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy

Who this might be right for
Malignant Melanoma
4SC AG 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT03122522
What this trial is testing

Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy

Who this might be right for
Metastatic Melanoma
Memorial Sloan Kettering Cancer Center 70
Large-scale testing (Phase 3)Ended earlyNCT02288377
What this trial is testing

A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)

Who this might be right for
Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours
Federation Francophone de Cancerologie Digestive 53
Testing effectiveness (Phase 2)Study completedNCT00165230
What this trial is testing

Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumor
Dana-Farber Cancer Institute 32
Testing effectiveness (Phase 2)Ended earlyNCT03993379
What this trial is testing

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

Who this might be right for
Solid TumorUnresectable or Metastatic Melanoma
CytomX Therapeutics 3
Early research (Phase 1)Study completedNCT03864042
What this trial is testing

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsMetastatic Melanoma
Pfizer 56
Testing effectiveness (Phase 2)Looking for participantsNCT05136196
What this trial is testing

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Who this might be right for
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8+22 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Ended earlyNCT03391050
What this trial is testing

APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma

Who this might be right for
Melanoma
Aprea Therapeutics 3
Testing effectiveness (Phase 2)Study completedNCT02230176
What this trial is testing

Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II

Who this might be right for
Pancreatic Neuroendocrine Carcinoma
Gustave Roussy, Cancer Campus, Grand Paris 84
Early research (Phase 1)WithdrawnNCT02300935
What this trial is testing

Study of Trametinib and Nab-paclitaxel in Patients With Melanoma

Who this might be right for
Melanoma
SCRI Development Innovations, LLC
Early research (Phase 1)Active Not RecruitingNCT05907304
What this trial is testing

Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations

Who this might be right for
Advanced or Metastatic Solid Tumors
Erasca, Inc. 86
Early research (Phase 1)Active Not RecruitingNCT04616248
What this trial is testing

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaPrognostic Stage IV Breast Cancer AJCC v8+10 more
University of Southern California 14
Not applicableEnded earlyNCT00730483
What this trial is testing

Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors

Who this might be right for
Gastrointestinal Carcinoid TumorIslet Cell TumorMetastatic Cancer
Yale University 13
Early research (Phase 1)Study completedNCT01910181
What this trial is testing

Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Hoffmann-La Roche 46
Testing effectiveness (Phase 2)Looking for participantsNCT07237100
What this trial is testing

Mirdametinib in Patients With Advanced NF1-mutant Melanoma

Who this might be right for
Advanced Unresectable MelanomaMetastatic Melanoma
Kevin Kim, MD 10
Testing effectiveness (Phase 2)Study completedNCT03484923
What this trial is testing

Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

Who this might be right for
Melanoma
Novartis Pharmaceuticals 196
Early research (Phase 1)Study completedNCT00418496
What this trial is testing

Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma

Who this might be right for
Renal CancerMelanoma
Ohio State University Comprehensive Cancer Center 17
Load More Results
150